GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response

神经病理学 共济失调 脊髓小脑共济失调 医学 运动障碍 内科学 自然史研究 心理学 疾病 自然史 精神科
作者
Carlo Wilke,David Pellerin,David Mengel,Andreas Traschütz,Matt C. Danzi,Marie‐Josée Dicaire,Manuela Neumann,Holger Lerche,Benjamin Bender,Henry Houlden,Jennifer Faber,Richard Roxburgh,José Luiz Pedroso,Paula Camila Alvez,Orlando Graziani Póvoas Barsottini,Chiara Pane,Francesco Saccà,Henry Houlden,Filippo M. Santorelli,Ivana Ricca,Stephan Züchner,Lüdger Schöls,Bernard Brais,Matthis Synofzik
出处
期刊:Brain [Oxford University Press]
卷期号:146 (10): 4144-4157 被引量:38
标识
DOI:10.1093/brain/awad157
摘要

Abstract Ataxia due to an autosomal dominant intronic GAA repeat expansion in FGF14 [GAA-FGF14 ataxia, spinocerebellar ataxia 27B (SCA27B)] has recently been identified as one of the most common genetic late-onset ataxias. We here aimed to characterize its phenotypic profile, natural history progression, and 4-aminopyridine (4-AP) treatment response. We conducted a multi-modal cohort study of 50 GAA-FGF14 patients, comprising in-depth phenotyping, cross-sectional and longitudinal progression data (up to 7 years), MRI findings, serum neurofilament light (sNfL) levels, neuropathology, and 4-AP treatment response data, including a series of n-of-1 treatment studies. GAA-FGF14 ataxia consistently presented as late-onset [60.0 years (53.5–68.5), median (interquartile range)] pancerebellar syndrome, partly combined with afferent sensory deficits (55%) and dysautonomia (28%). Dysautonomia increased with duration while cognitive impairment remained infrequent, even in advanced stages. Cross-sectional and longitudinal assessments consistently indicated mild progression of ataxia [0.29 Scale for the Assessment and Rating of Ataxia (SARA) points/year], not exceeding a moderate disease severity even in advanced stages (maximum SARA score: 18 points). Functional impairment increased relatively slowly (unilateral mobility aids after 8 years in 50% of patients). Corresponding to slow progression and low extra-cerebellar involvement, sNfL was not increased relative to controls. Concurrent second diseases (including progressive supranuclear palsy neuropathology) represented major individual aggravators of disease severity, constituting important caveats for planning future GAA-FGF14 trials. A treatment response to 4-AP with relevance for everyday living was reported by 86% of treated patients. A series of three prospective n-of-1 treatment experiences with on/off design showed marked reduction in daily symptomatic time and symptom severity on 4-AP. Our study characterizes the phenotypic profile, natural history progression, and 4-AP treatment response of GAA-FGF14 ataxia. It paves the way towards large-scale natural history studies and 4-AP treatment trials in this newly discovered, possibly most frequent, and treatable late-onset ataxia.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DW完成签到,获得积分10
1秒前
3秒前
4秒前
mandalorian发布了新的文献求助10
4秒前
molihuakai的应助被李家佳采纳,获得10
4秒前
阿猫发布了新的文献求助10
5秒前
5秒前
5秒前
一枚枕头发布了新的文献求助10
6秒前
沉静的机器猫完成签到 ,获得积分10
6秒前
7秒前
勤奋书桃完成签到,获得积分10
7秒前
文艺代灵发布了新的文献求助10
9秒前
顺利顺利完成签到 ,获得积分10
9秒前
10秒前
曙光发布了新的文献求助10
10秒前
shurong发布了新的文献求助10
10秒前
lobster发布了新的文献求助10
10秒前
11秒前
Lucas的应助被wxwx采纳,获得10
13秒前
13秒前
乐乐的应助被佳佳采纳,获得10
13秒前
yu晨发布了新的文献求助30
13秒前
科研通AI65的应助被玫瑰少年采纳,获得10
13秒前
阿猫完成签到,获得积分10
13秒前
13秒前
13秒前
14秒前
14秒前
14秒前
情怀的应助被Tracer采纳,获得10
14秒前
kento发布了新的文献求助30
15秒前
15秒前
Owen的应助被manman采纳,获得10
15秒前
清爽白薇完成签到,获得积分10
15秒前
李家佳发布了新的文献求助10
16秒前
16秒前
16秒前
17秒前
rzxhygr完成签到 ,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178742
求助须知:如何正确求助?哪些是违规求助? 9569473
关于积分的说明 21804902
捐赠科研通 7773828
什么是DOI,文献DOI怎么找? 3432923
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478542